One randomized trial in 29 people with treatment-resistant depression found a single ayahuasca dose produced a 57% reduction in depression scores at seven days versus placebo. Open-label and survey studies report similar improvements, but these designs cannot prove cause. Evidence past a few weeks is thin, and ayahuasca carries real psychiatric and medical risks.
What receptors does ayahuasca act on in the brain?
Ayahuasca's DMT acts as an agonist at serotonin receptors and sigma-1 receptors, according to a review of ayahuasca pharmacology. The brew pairs DMT from Psychotria viridis leaves with harmala alkaloids from the Banisteriopsis caapi vine, which block the MAO-A enzyme and allow DMT to become orally active and reach the brain. UC Berkeley's summary adds that ayahuasca may enhance neuroplasticity and structurally change parts of the default mode network.
- DMT is described in the pharmacology literature as an agonist at both serotonin receptors and sigma-1 receptors.
- Harmala alkaloids in B. caapi are reversible MAO-A inhibitors; without them, swallowed DMT is deactivated in the gut and produces no psychedelic effect.
- A systematic review of 28 studies reports ayahuasca activates frontal and paralimbic regions and decreases default mode network activity.
- Imaging of long-term users found increased cortical thickness in the anterior cingulate cortex and thinning in the posterior cingulate cortex, though association does not prove a therapeutic change.
Sources, checked November 15, 2026: Rapid antidepressant effects of the psychedelic ayahuasca in..., The Effects of Ayahuasca on Psychological Disorders: A Systematic..., Ayahuasca Therapy Information- UC Berkeley BCSP, Ayahuasca: A review of historical, pharmacological, and therapeutic...
Which studies tested ayahuasca for depression directly?
Three small clinical studies form the core evidence: a 2015 pilot in six patients with recurrent or major depressive disorder, a 2016 open-label trial in 17 patients with treatment-resistant depression, and a 2019 randomized placebo-controlled trial in 29 patients with treatment-resistant depression. All reported rapid symptom reductions within a day, with measured improvements lasting up to 21 days. A separate international survey of more than 10,000 users adds self-reported improvement rates, but cannot show cause.
| Study | Design and sample | Main finding | Main limitation |
|---|---|---|---|
| 2015 pilot (Osório et al.) | Open-label, 6 patients with depression | Up to 82% score reduction at days 1, 7 and 21 | No control group |
| 2016 trial (Sanches et al.) | Open-label, 17 patients with treatment-resistant depression | 61% HAM-D reduction, lasting 21 days | No placebo comparison |
| 2019 trial (Palhano-Fontes et al.) | Randomized, double-blind, placebo-controlled, 29 patients | 57% MADRS reduction at day 7 versus placebo | Small sample, one week follow-up |
| Global Ayahuasca Survey | Cross-sectional survey, 10,836 users | 94% of 1,580 with depression believed it improved | Retrospective self-report, no verification |
A review of the field concludes there are few controlled studies, with small samples, single doses only and short follow-ups. Read every number in the table above with that limit in mind. None of these studies tested repeated dosing, and none followed a controlled group beyond weeks.
Sources, checked November 15, 2026: Sub-acute and long-term effects of ayahuasca on affect and cognitive..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC, The Effects of Ayahuasca on Psychological Disorders: A Systematic..., Adverse effects of ayahuasca: Results from the Global Ayahuasca...
What should someone with depression actually do with this evidence?
Treat the ayahuasca findings as a research signal, not a treatment plan. The World Health Organization estimates about one-third of people do not respond to adequate courses of at least three antidepressants, which is the group most studied here. Questions about starting, stopping or changing medication belong with a licensed psychiatrist, and none of the cited studies instructs anyone to taper existing treatment.
- Bring the evidence to a treating clinician rather than acting on it alone. The 2019 trial required a roughly two-week medication washout under medical supervision, which is not something to reproduce independently.
- Ask about approved options with faster onset if that is the concern. A study of psychedelic retreats notes ketamine is a medically approved drug, which is why researchers treat it differently from ayahuasca.
- Be aware the trial authors reported a placebo response of 46% at day one, far above the 0 to 6% seen in ketamine trials, which makes ayahuasca's specific effect harder to isolate.
- Ayahuasca use is illegal in the United States because DMT is a Schedule I controlled substance, with limited religious exemptions under the Religious Freedom Restoration Act, per UC Berkeley's BCSP.
- Registered trials and their protocols can be checked on ClinicalTrials.gov; confirm current status directly with the listed research teams.
This page gives general information only and no medical advice. For individual questions about diagnosis, medication or eligibility for any study, speak with a licensed clinician who knows your history.
Sources, checked November 15, 2026: Rapid antidepressant effects of the psychedelic ayahuasca in..., A landscape analysis of psychedelic retreat organizations advertising..., Ayahuasca Therapy Information- UC Berkeley BCSP
How does ayahuasca work in the brain?
Ayahuasca combines two plants: the Banisteriopsis caapi vine, whose harmala alkaloids block the monoamine oxidase A enzyme, and Psychotria viridis leaves, which contain DMT. Orally on its own, DMT is deactivated in the gut by that enzyme and produces no psychedelic effect. The vine's inhibitors keep the enzyme from destroying DMT so it reaches the brain, producing an experience of roughly four to six hours. Researchers describe the psychoactive effects as primarily mediated by 5-HT2A serotonin receptors. See also what is ayahuasca.
On a timeline, subjective effects typically begin 30 to 60 minutes after drinking, peak between 60 and 120 minutes, and resolve by around 240 minutes. Peak DMT blood concentration occurs at about 1.5 hours, matching peak subjective effects, and alkaloid levels return to baseline within 24 hours.
Sources: Ayahuasca Therapy Information- UC Berkeley BCSP, Ayahuasca: An ancient sacrament for treatment of contemporary..., Ayahuasca: A review of historical, pharmacological, and therapeutic..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC
How long do the antidepressant effects of ayahuasca last?
Measured effects in clinical studies span from hours to 21 days, with weaker evidence beyond that point. The open-label study of 17 patients found symptom reductions beginning within a day and lowest scores 21 days later. A longitudinal observational study of ceremony attendees measured depression, anxiety and stress decreases that persisted at four weeks, though another study found no therapeutic effects four to seven years later.
In a one-year observational follow-up of 20 people with clinical depression who took ayahuasca once, BDI scores fell over time with 71% in remission. That study had no control group, so improvement cannot be attributed to ayahuasca alone. A separate one-year follow-up of 66 first-time ceremony attendees found depression and stress scores were statistically higher at six months than at seven days, suggesting early gains can fade.
Sources: Sub-acute and long-term effects of ayahuasca on affect and cognitive..., Ayahuasca: A review of historical, pharmacological, and therapeutic..., Long-term mental health and wellbeing outcomes associated with..., The Effects of Ayahuasca on Psychological Disorders: A Systematic...
Can ayahuasca help with anxiety as well as depression?
Some studies report anxiety reductions, but the designs are weak and results are mixed. A study of 57 ceremony attendees in the Netherlands and Colombia found stress and depression ratings dropped 36% and 46% the day after and stayed lower at four weeks. A four-week study of 73 participants found decreased stress and anxiety but no difference in depression. A randomized trial in 17 patients with social anxiety disorder found ayahuasca improved self-perception of speech performance five hours after intake. See also our anxiety research page.
| Study design | What it found on anxiety | Main limit |
|---|---|---|
| Naturalistic, 57 attendees | Stress and depression ratings lower next day and at 4 weeks | No control group |
| 73 participants over 4 weeks | Less stress and anxiety, no depression change | Self-report, uncontrolled |
| Randomized trial, 17 social anxiety patients | Better self-rated speech performance at 5 hours | Small sample, single time point |
| Survey of regular ayahuasca users | Lower anxiety vs non-users in the same communities | Cross-sectional, cannot show cause |
Sources: Sub-acute and long-term effects of ayahuasca on affect and cognitive..., The Effects of Ayahuasca on Psychological Disorders: A Systematic..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC
Who should avoid ayahuasca?
The Alcohol and Drug Foundation states that ayahuasca can trigger or worsen conditions such as anxiety, schizophrenia or psychosis, and that anyone with a history of these issues, or a family history of mental health conditions, should avoid it. A review of safety data concludes ayahuasca should be avoided by people with certain pre-existing mental conditions and by pregnant women. If you take any psychiatric medication, ask a licensed clinician before changing or pausing anything.
- People with a personal history of anxiety, schizophrenia or psychosis, or a family history of mental health conditions, per the ADF.
- Pregnant women, based on animal findings of possible developmental toxicity.
- People taking antidepressants or other serotonergic drugs: combining them with ayahuasca risks serotonin syndrome, which can be life-threatening, and harmala alkaloids interact with drugs metabolized by CYP2D6, CYP1A1 and CYP3A4 enzymes.
- People with a physical health condition: survey analysis found this raised the odds of both physical and mental adverse effects.
- People with an anxiety disorder: an anxiety diagnosis raised the odds of adverse mental health effects in the Global Ayahuasca Survey analysis.
Sources: Ayahuasca - Alcohol and Drug Foundation, Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity..., Ayahuasca: What It Is and Risks, Ayahuasca: pharmacology, safety, and therapeutic effects - PMC
What are the physical side effects of ayahuasca?
Nausea and vomiting are the most common physical effects. In the Global Ayahuasca Survey, about 70% of more than 10,000 respondents reported physical side effects, most often nausea and vomiting, and only 2.3% needed medical attention. Experimental studies also list diarrhea, abdominal pain, headache, transient anxiety and moderate short-lived increases in blood pressure and heart rate among common effects.
In controlled pharmacology trials with 24 subjects at DMT doses of 0.5 to 1 mg per kg, ayahuasca was described as well tolerated, though one subject had an intensely dysphoric reaction lasting 20 minutes without needing medication. See also our page on risks and screening.
Sources: Ayahuasca: What It Is and Risks, Adverse effects of ayahuasca: Results from the Global Ayahuasca..., Ayahuasca: pharmacology, safety, and therapeutic effects - PMC, Ayahuasca: An ancient sacrament for treatment of contemporary...
Can ayahuasca cause mental illness?
It can worsen existing vulnerabilities and, in rare reports, has been followed by psychiatric problems. A prospective study of 40 ceremony participants found 7 with extremely challenging psychological reactions, some involving psychotic symptoms, and 4 of those 7 had a prior psychiatric diagnosis. A case report describes a 42-year-old man with no significant psychiatric history who developed suspected substance-induced psychosis after repeated DMT combined with long-term cannabis use, resolving after three weeks of treatment.
On the other side, a systematic review of 28 human studies reported that neither acute nor long-term ayahuasca use was associated with increased psychopathology or cognitive deficits in the populations studied. And in the Global Ayahuasca Survey, 55.9% reported adverse mental health effects in the weeks or months after use, but about 88% viewed them as part of a positive process of growth or integration. These are averages across mostly healthy users, not a guarantee for any individual.
Sources: Adverse effects of ayahuasca: Results from the Global Ayahuasca..., Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity...
What is the best psychedelic for depression?
There is no single best psychedelic for depression, and none is approved by U.S. regulators as a depression treatment. Ayahuasca's evidence rests mainly on one 29-person randomized trial plus small open-label and observational studies. A meta-review cited by UC Berkeley found psilocybin, ayahuasca and LSD could be effective for drug dependence, anxiety and mood disorders, but that is a broad finding, not a ranking.
Ketamine differs in that it is already a medically approved drug and is legal for clinical use, which is one reason researchers exclude it from psychedelic retreat studies. For ayahuasca specifically, the trial's own authors noted a placebo response of 46% at day one, far above the 0 to 6% seen in ketamine trials, which makes ayahuasca's comparative effect harder to isolate. See also our ayahuasca versus psilocybin comparison.
Sources: Ayahuasca: A review of historical, pharmacological, and therapeutic..., Ayahuasca Therapy Information- UC Berkeley BCSP, Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSD, A landscape analysis of psychedelic retreat organizations advertising...
Does ayahuasca change your brain or personality?
Long-term use is associated with measurable brain differences, but association is not proof of rewiring. Imaging studies of people who used ayahuasca at least 50 times in two years found increased cortical thickness in the anterior cingulate cortex and thinning of the posterior cingulate cortex. UC Berkeley's summary of long-term effects states ayahuasca may enhance neuroplasticity and structurally change parts of the default mode network, and that long-term use has been shown to produce changes in brain chemistry and personality.
A rat study found some neurodegeneration during treatment but no permanent damage by the end of the 14-day study. Whether any of these changes help or harm a given person with depression is not established, so treat claims that ayahuasca rewires the brain as unproven shorthand.
Sources: Ayahuasca: An ancient sacrament for treatment of contemporary..., Ayahuasca Therapy Information- UC Berkeley BCSP, Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity...
Is ayahuasca a miracle cure for depression?
No. The evidence shows rapid short-term signal in small studies with real limitations. The World Health Organization estimates around 280 million people live with depression and about one-third do not respond to adequate courses of antidepressants, which is why fast-acting alternatives attract attention. But the single randomized ayahuasca trial had only 29 participants, and surveys rely on self-report. Anyone presenting ayahuasca as a cure is going beyond what any cited study shows.
Sources: The Effects of Ayahuasca on Psychological Disorders: A Systematic..., Rapid antidepressant effects of the psychedelic ayahuasca in..., Ayahuasca: A review of historical, pharmacological, and therapeutic...
What did the randomized trial find?
A hospital trial randomized 29 adults with treatment-resistant unipolar depression to ayahuasca or placebo. Depression scores were lower in the ayahuasca group at days one, two and seven. At day seven, MADRS response was 64% versus 27% (p=0.04); remission was 36% versus 7% (p=0.054).
Response and remission are different endpoints. The remission comparison did not meet the conventional 0.05 threshold. Neither endpoint establishes lasting recovery.
What do the larger survey numbers describe?
The international survey included 11,912 respondents overall. Its relevant depression subgroup was 1,571 people reporting depression at use. Of that subgroup, 78% described symptoms as very much improved or completely resolved, while 2.7% reported worsening.
These are retrospective perceptions. Survey wording such as completely resolved does not establish clinician-verified remission. A large respondent count can provide useful descriptive information without answering the causal question. People chose to participate, recalled earlier experiences and did not share a randomized untreated comparison. Sample size does not remove those design limits.
What do newer and contextual studies add?
A September 2026 cancer-related feasibility study included six female participants and no control group. Its abstract reports depression and anxiety symptom reductions through three weeks. Assessments also occurred at three months, but the abstract does not establish positive results at that point.
A separate placebo-controlled study of experienced retreat participants found depression, anxiety and stress decreases in both active and placebo groups. This makes context and expectation relevant to interpreting retreat observations. It does not erase the hospital trial's finding or supply independent proof that a retreat treats depression.
How should these results inform a treatment conversation?
Organize the evidence by study design before comparing headlines. Ask which diagnosis was assessed, what counted as improvement, what the comparison group received and how long outcomes were followed. Those details reveal where a finding ends.
The registered hospital study used psychiatric assessment and exclusions. Its setting differs from an ordinary purchased retreat. A clinical discussion should consider the person's current care and individual risks without assuming that an advertised program reproduces research conditions. These findings provide no instruction to stop, taper or substitute established treatment, and this article cannot assess personal eligibility.
What does the placebo-controlled retreat study actually add?
A separate placebo-controlled study examined experienced participants in ayahuasca group retreats, measuring depression, anxiety and stress outcomes. Its notable finding is that symptom decreases appeared in both the active and placebo groups. This section is summarized here without participant count or follow-up window, because those figures are not established in the material supplied; readers should check the published study for those details.
What the study contributes is context, not proof. When both groups improve, expectation, group setting, rest and self-selection become part of the explanation. That matters for two common claims. First, it cautions against reading retreat testimonials as evidence of specific treatment effect: participants sincerely report improvement that a comparison would attribute partly to context. Second, it tempers the reverse claim: the placebo result does not erase the hospital trial, which used randomization and a control in a different population and setting.
The honest summary is that context and expectation are measurable parts of retreat observations, and a well-designed comparison makes them visible. A reader evaluating a commercial program can ask what improvement claims rest on, and expect an answer that acknowledges this literature rather than citing only favorable numbers.
For personal decisions, none of these studies instructs starting, stopping or substituting treatment. Decisions about existing care belong with the treating professional, with the evidence organized by design as above.
What else should you ask?
How quickly did antidepressant effects appear in the studies?
Fast. The 2016 open-label trial in 17 patients found significant depression reduction within the first hours after a single dose, and a review notes the 2015 pilot saw reductions within a day. Lowest scores appeared at later assessments, around 21 days.
Did any study test pure DMT instead of ayahuasca for depression?
Yes. A phase I open-label study gave intravenous DMT with psychological support to 7 treatment-resistant depression patients and 3 healthy controls, reporting a 15% decrease in depressive symptoms one day after a second dosing session. It was not ayahuasca and had no control group.
Is combining ayahuasca with antidepressants dangerous?
It can be. Because ayahuasca contains MAO inhibitors, combining it with SSRIs can be dangerous, per the Alcohol and Drug Foundation, and a pharmacology review states the combination may cause serotonin syndrome, which can be fatal, though such cases appear rare in experimental settings.
Who was excluded from the 2019 randomized trial?
The trial excluded people with previous ayahuasca experience, current medical disease, pregnancy, neurological disorders, personal or family history of schizophrenia, bipolar disorder, mania or hypomania, substance abuse, and suicidal risk. Its results do not transfer to people with those characteristics.
Can a doctor legally prescribe ayahuasca for depression in the United States?
No. UC Berkeley's BCSP states ayahuasca use and therapy are illegal in the United States because DMT is a Schedule I controlled substance, with exemptions granted only for specific religious groups under the Religious Freedom Restoration Act. There is no prescription pathway.
What do psychiatrists think of ayahuasca?
A published review of human studies concludes that acute ayahuasca administration to healthy volunteers has an acceptable safety profile with a narrow safety margin, and that it should be avoided by those with certain pre-existing mental conditions and by pregnant women. Cleveland Clinic sources note that combining ayahuasca with medications that raise serotonin levels risks serotonin syndrome, which can range from mild to life-threatening, and that Schedule I status makes ayahuasca very hard to study in the U.S.
Can ayahuasca make anxiety worse?
Yes. The Alcohol and Drug Foundation states ayahuasca can trigger or worsen anxiety, and survey analysis found an anxiety disorder raised the odds of adverse mental health effects after use. Transient anxiety during sessions is also among the most common effects in experimental studies.
Does ayahuasca cause brain damage?
Human reviews of 28 studies found no increased psychopathology or cognitive deficits with acute or long-term use. A rat study showed some neurodegeneration during treatment but no permanent damage at 14 days. No study proves safety for every individual, especially outside supervised settings.
What is treatment-resistant depression?
In the ayahuasca trial it was defined as unipolar major depressive disorder in adults aged 18 to 60 with inadequate response to at least two antidepressants from different classes. WHO estimates about one-third of people with depression do not respond to adequate antidepressant courses.
Is ayahuasca legal in the United States?
No. DMT, ayahuasca's main psychoactive compound, has been a Schedule I controlled substance under federal law since 1970. Brazil has allowed ayahuasca for ritual use since 1987. This is general information, not legal advice; see our legality page for details.
How many ayahuasca depression studies exist?
The core clinical evidence is one randomized placebo-controlled trial of 29 patients, plus two small open-label studies of 6 and 17 patients and one secondary suicidality analysis. The rest of the literature consists of surveys, observational and naturalistic studies.
Can ayahuasca help with childhood trauma or PTSD?
A small case series of eight veterans with PTSD reported reliable symptom changes by post-treatment in most participants, maintained by 70% at three months. That is preliminary, uncontrolled evidence. See our PTSD research page for detail.
Are there ayahuasca clinical trials I can look up?
The main randomized depression trial is registered at clinicaltrials.gov under NCT02914769, conducted at Onofre Lopes University Hospital in Natal, Brazil. You can search clinicaltrials.gov for current ayahuasca studies and talk to a clinician about whether any trial fits your situation.
Do people report depression after ayahuasca?
Some do. In the Global Ayahuasca Survey, 4.5% of respondents with diagnosed depression and 2.7% with diagnosed anxiety considered their symptoms worsened after consumption. A majority reporting adverse mental health effects said they lasted under a week.
Is ayahuasca addictive?
One controlled study found no tolerance or sensitization after two ayahuasca doses four hours apart, and reviews report no increased psychopathology with long-term ritual use. That is different from a guarantee of non-addictiveness for every user, and it is not medical advice.
Why is randomization useful in depression research?
It can reduce systematic differences between comparison groups. It does not remove every potential source of bias.
Which depression population was studied?
The trial involved treatment-resistant unipolar depression.
Does treatment-resistant mean depression cannot improve?
It describes previous inadequate response under defined criteria. The label alone cannot foretell future outcomes.
Was the response result statistically significant?
The reported day-seven MADRS response comparison had p=0.04.
Was the remission comparison statistically significant?
Its reported p=0.054 did not meet the conventional 0.05 threshold.
Are response and remission interchangeable?
They are separately defined endpoints. Report each result using the definition and measure specified in that study.
What is MADRS?
It is a depression symptom-rating scale. A score change needs the study's assessment context and endpoint definition.
Does statistical significance tell me my chance of improvement?
It evaluates a statistical comparison under a model. It does not supply an individual treatment prediction.
How long did the randomized depression study follow outcomes?
Its reported depression assessments extended through day seven.
Were all 11,912 survey respondents depression patients?
No. The depression subgroup contained 1,571 respondents.
Does survey wording establish medical remission?
No. That response described perceived resolution.
Were negative survey outcomes reported?
Yes. 2.7% of the depression subgroup reported worsening.
What does the new cancer study contribute?
It adds a six-person uncontrolled observation, rather than confirmatory efficacy evidence.
Did that study establish three-month benefit?
The abstract reports reductions through three weeks; a later assessment does not establish a positive result.
Why mention the placebo retreat study?
Improvement in both groups shows why context and expectation should be considered when interpreting retreat observations.
Does research mean a commercial retreat provides depression treatment?
A business must establish its actual clinical services and authority separately. Citing a trial cannot establish those facts.
Does this evidence support changing current medicines?
This article supplies no instruction to alter treatment. Decisions about existing care belong with the treating professional.
Can the results be assumed to apply to bipolar depression?
A finding in one specified population cannot automatically be extended to another diagnosis.
What evidence would address lasting benefit?
Longer, adequately controlled follow-up with clearly defined outcomes would address a different question from a short-term score change.
Is ayahuasca good for depression?
A small randomized trial reported short-term symptom improvements in selected adults, while surveys describe perceived changes and some worsening. These findings do not establish a commercial-retreat treatment or personal suitability.
Where does this guidance come from?
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialRandomized hospital depression outcomes, separate response/remission interpretation and seven-day limits.
- Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant DepressionRegistration of the same trial; not a separate replication.
- Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumersDepression subgroup, perceived outcomes and reported worsening in a retrospective survey.
- Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept TrialSix-person cancer-related feasibility study; three-week abstract result and unestablished three-month benefit.
- A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreatsBoth-group symptom changes in a small placebo-controlled retreat study.
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized...Official government source, checked November 15, 2026.
- Ayahuasca: pharmacology, safety, and therapeutic effects - PMCOfficial government source, checked November 15, 2026.
- Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association...Official government source, checked November 15, 2026.
- Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review - PMCOfficial government source, checked November 15, 2026.
- Ayahuasca Therapy Information- UC Berkeley BCSPChecked November 15, 2026.
- Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness? - PMCOfficial government source, checked November 15, 2026.
- Ayahuasca: A review of historical, pharmacological, and therapeutic aspects - PMCOfficial government source, checked November 15, 2026.
- Long-term mental health and wellbeing outcomes associated with naturalistic ayahuasca consumption - PMCOfficial government source, checked November 15, 2026.
- The Effects of Ayahuasca on Psychological Disorders: A Systematic Literature Review - PMCOfficial government source, checked November 15, 2026.
- Ayahuasca - Alcohol and Drug FoundationChecked November 15, 2026.
- Ayahuasca: What It Is and RisksChecked November 15, 2026.
- Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey - PMCOfficial government source, checked November 15, 2026.
- Psychedelic-Assisted Therapy for PTSD - PTSD: National Center for PTSDOfficial government source, checked November 15, 2026.
- A landscape analysis of psychedelic retreat organizations advertising online - PMCOfficial government source, checked November 15, 2026.
- Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental...Official government source, checked November 15, 2026.
- Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military...Official government source, checked November 15, 2026.
Read our editorial standards and the risk and screening guide.